Q-omics provides the consensus-scored WASHC5 profile across patient tissues and cancer cell-line models. WASHC5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, WASHC5 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, WASHC5 RNA expression shows 19,711 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where WASHC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WASHC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WASHC5 survival associations across molecular data types. WASHC5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WASHC5 RNA expression–survival associations across cancer types. High WASHC5 expression shows unfavorable associations in UVM, BLCA, LIHC, LUSC and LUAD, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for WASHC5 RNA expression.
This table summarizes WASHC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for WASHC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WASHC5 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, STAD, COAD and BLCA. The HNSC box plot shows higher WASHC5 RNA expression in tumor versus normal tissue (log2 FC = +1.490, t-test p < 0.001).
This table shows molecular features associated with WASHC5 in patient tissues and cancer cell lines. In patient samples, WASHC5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, WASHC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
